Suppr超能文献

比较使用电子数据源识别心力衰竭患者的方法。

Comparing methods for identifying patients with heart failure using electronic data sources.

机构信息

Henry Ford Heart and Vascular Institute, Henry Ford Hospital, 2799 W, Grand Blvd,, Detroit, MI 48202, USA.

出版信息

BMC Health Serv Res. 2009 Dec 18;9:237. doi: 10.1186/1472-6963-9-237.

Abstract

BACKGROUND

Accurately identifying heart failure (HF) patients from administrative claims data is useful for both research and quality of care efforts. Yet, there are few comparisons of the various claims data criteria (also known as claims signatures) for identifying HF patients. We compared various HF claim signatures to assess their relative accuracy.

METHODS

In this retrospective study, we identified 4174 patients who received care from a large health system in southeast Michigan and who had >or=1 HF encounter between January 1, 2004 and December 31, 2005. Four hundred patients were chosen at random and a detailed chart review was performed to assess which met the Framingham HF criteria. The sample was divided into 300 subjects for derivation and 100 subjects for validation. Sensitivity, specificity,, and area under the curve (AUC) were determined for the various claim signatures. The criteria with the highest AUC were retested in the validation set.

RESULTS

Of the 400 patients sampled, 65% met Framingham HF criteria, and 56% had at least one B-type Natriuretic Peptide (BNP) measurement. There was substantial variation between claims signatures in terms of sensitivity (range 15%-77%) and specificity (range 69%-100%). The best performing criteria in the derivation set was if patients met any one of the following: >or=2 HF encounters, any hospital discharge diagnosis of HF, or a BNP >or=200 pg/ml. These criteria showed a sensitivity of 76%, specificity of 75%, and AUC of 0.754 for meeting the Framingham HF criteria. This claims signature performed similarly in the validation set.

CONCLUSION

Claim signatures for HF vary greatly in their relative sensitivity and specificity. These findings may facilitate efforts to identify HF patients for research and quality improvement efforts.

摘要

背景

准确地从行政索赔数据中识别心力衰竭(HF)患者对于研究和护理质量都很有用。然而,用于识别 HF 患者的各种索赔数据标准(也称为索赔特征)之间几乎没有比较。我们比较了各种 HF 索赔特征,以评估它们的相对准确性。

方法

在这项回顾性研究中,我们确定了 4174 名在密歇根州东南部的一家大型医疗系统接受治疗的患者,他们在 2004 年 1 月 1 日至 2005 年 12 月 31 日期间有>或=1 次 HF 就诊。随机选择了 400 名患者,并进行了详细的病历审查,以评估哪些患者符合弗雷明汉 HF 标准。该样本分为 300 名受试者用于推导,100 名受试者用于验证。确定了各种索赔特征的敏感性、特异性、阳性预测值和曲线下面积(AUC)。在验证集中重新测试 AUC 最高的标准。

结果

在抽样的 400 名患者中,65%符合弗雷明汉 HF 标准,56%至少有一次 B 型利钠肽(BNP)测量。在敏感性(范围 15%-77%)和特异性(范围 69%-100%)方面,索赔特征之间存在很大差异。在推导集中表现最好的标准是,如果患者符合以下任何一种情况:>或=2 次 HF 就诊、任何 HF 出院诊断或 BNP >或=200 pg/ml。这些标准对符合弗雷明汉 HF 标准的患者的敏感性为 76%、特异性为 75%、AUC 为 0.754。该索赔特征在验证集中表现相似。

结论

HF 的索赔特征在相对敏感性和特异性方面差异很大。这些发现可能有助于识别 HF 患者进行研究和质量改进工作。

相似文献

1
Comparing methods for identifying patients with heart failure using electronic data sources.
BMC Health Serv Res. 2009 Dec 18;9:237. doi: 10.1186/1472-6963-9-237.
3
6
A systematic review of validated methods for identifying heart failure using administrative data.
Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1(0 1):129-40. doi: 10.1002/pds.2313.
7
B-type natriuretic peptide testing and the accuracy of heart failure diagnosis in the emergency department.
Circ Heart Fail. 2010 Jan;3(1):104-10. doi: 10.1161/CIRCHEARTFAILURE.109.869438. Epub 2009 Nov 20.
8
B-type natriuretic peptide as a marker for heart failure in patients with acute stroke.
Intensive Care Med. 2007 Sep;33(9):1587-93. doi: 10.1007/s00134-007-0704-1. Epub 2007 May 31.
9
Testing for BNP and NT-proBNP in the diagnosis and prognosis of heart failure.
Evid Rep Technol Assess (Full Rep). 2006 Sep(142):1-147.

引用本文的文献

6
Applying computable phenotypes within a common data model to identify heart failure patients for an implantable cardiac device registry.
Int J Cardiol Heart Vasc. 2022 Feb 19;39:100974. doi: 10.1016/j.ijcha.2022.100974. eCollection 2022 Apr.
7
Risk of clinically relevant hyperglycemia with metoprolol compared to carvedilol in older adults with heart failure and diabetes.
Pharmacoepidemiol Drug Saf. 2021 Oct;30(10):1420-1427. doi: 10.1002/pds.5303. Epub 2021 Jun 14.
9
Effectiveness of beta blockers in patients with and without a history of myocardial infarction.
Eur J Clin Pharmacol. 2020 Aug;76(8):1161-1168. doi: 10.1007/s00228-020-02886-0. Epub 2020 May 22.
10
Risk Prediction in Transition: MAGGIC Score Performance at Discharge and Incremental Utility of Natriuretic Peptides.
J Card Fail. 2020 Jan;26(1):52-60. doi: 10.1016/j.cardfail.2019.11.016. Epub 2019 Nov 18.

本文引用的文献

2
Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients.
Eur Heart J. 2008 Apr;29(8):1011-8. doi: 10.1093/eurheartj/ehn023. Epub 2008 Feb 9.
3
Prognostic value of a novel classification scheme for heart failure: the Minnesota Heart Failure Criteria.
Am J Epidemiol. 2006 Jul 15;164(2):184-93. doi: 10.1093/aje/kwj168. Epub 2006 May 17.
4
Gender and risk of adverse outcomes in heart failure.
Am J Cardiol. 2004 Nov 1;94(9):1147-52. doi: 10.1016/j.amjcard.2004.07.081.
6
Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure.
N Engl J Med. 2002 Jul 18;347(3):161-7. doi: 10.1056/NEJMoa020233.
9
The natural history of congestive heart failure: the Framingham study.
N Engl J Med. 1971 Dec 23;285(26):1441-6. doi: 10.1056/NEJM197112232852601.
10
Prevalence and mortality rate of congestive heart failure in the United States.
J Am Coll Cardiol. 1992 Aug;20(2):301-6. doi: 10.1016/0735-1097(92)90094-4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验